These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 1388772)

  • 21. Dopamine D2 receptors labeled with [3H]raclopride in rat and rabbit brains. Equilibrium binding, kinetics, distribution and selectivity.
    Dewar KM; Montreuil B; Grondin L; Reader TA
    J Pharmacol Exp Ther; 1989 Aug; 250(2):696-706. PubMed ID: 2527300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotonin 5-HT3 and dopamine D2 receptor antagonistic activity.
    Hirokawa Y; Fujiwara I; Suzuki K; Harada H; Yoshikawa T; Yoshida N; Kato S
    J Med Chem; 2003 Feb; 46(5):702-15. PubMed ID: 12593651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine D2 receptors mapped in rat brain with [3H](+)PHNO.
    Nobrega JN; Seeman P
    Synapse; 1994 Jul; 17(3):167-72. PubMed ID: 7974199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dopamine D2 receptor binding sites for agonists. A tetrahedral model.
    Seeman P; Watanabe M; Grigoriadis D; Tedesco JL; George SR; Svensson U; Nilsson JL; Neumeyer JL
    Mol Pharmacol; 1985 Nov; 28(5):391-9. PubMed ID: 2932631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. (Aryloxy)alkylamines as selective human dopamine D4 receptor antagonists: potential antipsychotic agents.
    Unangst PC; Capiris T; Connor DT; Doubleday R; Heffner TG; MacKenzie RG; Miller SR; Pugsley TA; Wise LD
    J Med Chem; 1997 Dec; 40(25):4026-9. PubMed ID: 9406594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel benzamides as selective and potent gastrokinetic agents. III. Synthesis and structure-activity relationships of 4-amino-5-chloro-2-methoxy- and 2-ethoxy-N-[(4-substituted 2-morpholinyl)methyl]-benzamides.
    Kato S; Morie T; Harada H; Yoshida N; Matsumoto J
    Chem Pharm Bull (Tokyo); 1992 Mar; 40(3):652-60. PubMed ID: 1535291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simple and highly predictive QSAR method: application to a series of (S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-methoxybenzamides.
    Freitas MP; Martins JA
    Talanta; 2005 Jul; 67(1):182-6. PubMed ID: 18970153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PLS-based quantitative structure-activity relationship for substituted benzamides of clebopride type. Application of experimental design in drug design.
    Norinder U; Högberg T
    Acta Chem Scand (Cph); 1992 Apr; 46(4):363-6. PubMed ID: 1515282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Benzotriazinones as "virtual ring" mimics of o-methoxybenzamides: novel and potent 5-HT3 receptor antagonists.
    King FD; Dabbs S; Bermudez J; Sanger GJ
    J Med Chem; 1990 Nov; 33(11):2942-4. PubMed ID: 2231593
    [No Abstract]   [Full Text] [Related]  

  • 30. The influence of aromatic substituents on the binding of substituted benzamides to dopamine D-2 receptors: congruent QSAR and MEP analyses.
    Testa B; el Tayar N; Carrupt PA; Van de Waterbeemd H; Kilpatrick GJ; Jenner P; Marsden CD
    J Pharm Pharmacol; 1987 Sep; 39(9):767-8. PubMed ID: 2890751
    [No Abstract]   [Full Text] [Related]  

  • 31. Experimental design-based quantitative structure-toxicity relationship of some local anaesthetics using the PLS method.
    Norinder U
    J Appl Toxicol; 1992 Apr; 12(2):143-7. PubMed ID: 1556382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A note on the metabolism of o-(2-ethoxyethoxy)-benzamide to o-(carbamoyl) phenoxyacetic acid in man.
    CUMMINGS AJ
    J Pharm Pharmacol; 1963 Mar; 15():212-4. PubMed ID: 14024236
    [No Abstract]   [Full Text] [Related]  

  • 33. Electrostatic potentials from charge-density studies of benzamide at 123 K.
    Ruble JR; Galvao A
    Acta Crystallogr B; 1995 Oct; 51 ( Pt 5)():835-8. PubMed ID: 7576376
    [No Abstract]   [Full Text] [Related]  

  • 34. A multiway 3D QSAR analysis of a series of (S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-6-methoxybenzamides.
    Nilsson J; Homan EJ; Smilde AK; Grol CJ; Wikström H
    J Comput Aided Mol Des; 1998 Jan; 12(1):81-93. PubMed ID: 9570091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A quantitative structure-activity relationship for some dopamine D2 antagonists of benzamide type.
    Norinder U; Högberg T
    Acta Pharm Nord; 1992; 4(2):73-8. PubMed ID: 1388772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The development of dopamine D2-receptor selective antagonists.
    Högberg T
    Drug Des Discov; 1993; 9(3-4):333-50. PubMed ID: 8400011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. QSAR modeling on dopamine D2 receptor binding affinity of 6-methoxy benzamides.
    Samanta S; Debnath B; Gayen S; Ghosh B; Basu A; Srikanth K; Jha T
    Farmaco; 2005 Oct; 60(10):818-25. PubMed ID: 16055122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GRID/GOLPE 3D quantitative structure-activity relationship study on a set of benzamides and naphthamides, with affinity for the dopamine D3 receptor subtype.
    Nilsson J; Wikström H; Smilde A; Glase S; Pugsley T; Cruciani G; Pastor M; Clementi S
    J Med Chem; 1997 Mar; 40(6):833-40. PubMed ID: 9083471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. QSAR prediction of D2 receptor antagonistic activity of 6-methoxy benzamides.
    Fatemi MH; Dorostkar F
    Eur J Med Chem; 2010 Nov; 45(11):4856-62. PubMed ID: 20728966
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.